Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Citius Oncology, Inc.NASDAQ: CTOR
Other Income / Expenses · Q2 FY2026 · quarter ended Mar 2026
Other income / expenses remains negative
Q2 FY2026 other income / expenses was $1.77M, compared with $0 a year earlier. Trailing-twelve-month other income / expenses was $1.57M.
Context
- Other income / expenses increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near $1.77M or moves back toward the trailing-twelve-month quarterly average of $393.37K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (181.66K) USD
- Year-over-year change
- —
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (181.66K) | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Other Income / Expenses vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 other income / expenses of $1.57M is the 6th highest of the 10 companies compared; the peer median is $1.99M.
- Other income / expenses amounts to 28.0% of revenue for CTOR, versus a peer median of 115.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $45.95M | +197.9% | — | 79.6% | |
| LTM Mar 2026 | $40.74M | -24.4% | — | 3552.1% | |
| LTM Mar 2026 | $9.52M | -61.3% | -24.7% | 150.7% | |
| LTM Mar 2026 | $2.53M | +109.2% | +414.8% | — | |
| LTM Mar 2026 | $1.99M | -54.2% | — | 3.6% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $1.57M | — | — | 28.0% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $299.11K | +119.3% | +78.0% | — |
| LTM Mar 2026 | -$34.98M | -816.0% | — | 32.7% | |
| LTM Mar 2026 | -$116.93M | -775.7% | — | 345.3% | |
| LTM Mar 2026 | -$509.57M | -14437.9% | — | — | |
| Peer median (excluding CTOR) | $1.99M | -54.2% | +78.0% | 115.2% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.